ATE524194T1 - Antigene polypeptide - Google Patents

Antigene polypeptide

Info

Publication number
ATE524194T1
ATE524194T1 AT06011195T AT06011195T ATE524194T1 AT E524194 T1 ATE524194 T1 AT E524194T1 AT 06011195 T AT06011195 T AT 06011195T AT 06011195 T AT06011195 T AT 06011195T AT E524194 T1 ATE524194 T1 AT E524194T1
Authority
AT
Austria
Prior art keywords
polypeptides
antigen polypeptides
vaccines
identification
manufacture
Prior art date
Application number
AT06011195T
Other languages
English (en)
Inventor
Simon Foster
Kirsty Brummel
Philip Mcdowell
Simon Clarke
Original Assignee
Univ Sheffield
Biosynexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sheffield, Biosynexus Inc filed Critical Univ Sheffield
Application granted granted Critical
Publication of ATE524194T1 publication Critical patent/ATE524194T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT06011195T 2000-06-20 2001-06-20 Antigene polypeptide ATE524194T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0014907.0A GB0014907D0 (en) 2000-06-20 2000-06-20 Antigenic polypeptides

Publications (1)

Publication Number Publication Date
ATE524194T1 true ATE524194T1 (de) 2011-09-15

Family

ID=9893906

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06011195T ATE524194T1 (de) 2000-06-20 2001-06-20 Antigene polypeptide
AT01940746T ATE386806T1 (de) 2000-06-20 2001-06-20 Antigene polypeptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01940746T ATE386806T1 (de) 2000-06-20 2001-06-20 Antigene polypeptide

Country Status (12)

Country Link
US (3) US20030186275A1 (de)
EP (4) EP1710311B1 (de)
JP (2) JP2004500883A (de)
CN (2) CN102021184A (de)
AT (2) ATE524194T1 (de)
AU (4) AU7424801A (de)
BR (1) BR0111823A (de)
CA (2) CA2412504C (de)
DE (1) DE60132893T2 (de)
GB (1) GB0014907D0 (de)
NO (1) NO20025838L (de)
WO (1) WO2001098499A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP2339344A1 (de) * 2001-06-15 2011-06-29 Inhibitex, Inc. Kreuzreaktive monoklonale und polyklonale Antikörper, die Oberflächenprotein aus koagulasenegativen Staphylococci und Staphylococcus Aureus erkennen
EP1412379B1 (de) * 2001-08-02 2012-01-25 The University Of Sheffield Impfstoff
WO2013034682A1 (en) * 2011-09-08 2013-03-14 Umc Utrecht Holding B.V. Vaccine based on staphylococcal superantigen- line 3 protein (ssl3)
AU2003254555A1 (en) * 2002-07-26 2004-02-23 Intercell Ag S. aureus antigene
WO2004094467A2 (en) * 2003-04-22 2004-11-04 Intercell Ag H. pylori antigens
NZ544542A (en) * 2003-07-24 2009-01-31 Merck & Co Inc Polypeptides for inducing a protective immune response against staphylococcus aureus
CN1918176A (zh) * 2004-02-18 2007-02-21 默克公司 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
FR2871159A1 (fr) * 2004-06-08 2005-12-09 Abag Sa Nouvelles proteines permettant, notamment, la mise en evidence in vitro et la prevention des infections a staphylocoques a coagulase negative
FR2871237B1 (fr) * 2004-06-08 2011-03-11 Abag Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections staphylococciques sur protheses articulaires et autres materiels etrangers implantes
US8729013B2 (en) 2004-08-26 2014-05-20 The University Of Western Ontario Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
ES2730275T3 (es) 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
BRPI0516974A (pt) 2004-10-21 2008-09-30 Wyeth Corp composição imunogênica compreendendo um polipeptìdeo; um método para induzir uma resposta imune contra staphylococcus epidermidis; um método para induzir uma resposta imune contra staphylococcus aureus; um método para a detecção e/ou identificação de staphylococcus epidermidis; um método para a detecção e/ou identificação de anticorpos para staphylococcus epidermidis
WO2006078680A2 (en) 2005-01-21 2006-07-27 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
KR20100072228A (ko) 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
CN102292105A (zh) 2008-11-26 2011-12-21 默沙东公司 用于诱导抗金黄色葡萄球菌的保护性免疫应答的多肽
EP2376111A4 (de) 2008-11-26 2013-01-09 Merck Sharp & Dohme Polypeptide zur induzierung einer schützenden immunantwort gegen staphylococcus aureus
US8101190B2 (en) * 2009-03-03 2012-01-24 Ingen Biosciences Method for diagnosing staphylococcal infections
HRP20160274T1 (hr) 2009-04-03 2016-04-08 University Of Chicago Pripravci i metode vezane za varijante proteina a (spa)
AU2010251156C1 (en) * 2009-05-18 2015-02-05 Julius-Maximilians-Universitat Wurzburg Antibodies or fragments thereof directed against a Staphylococcus aureus epitope of IsaA or IsaB
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2555794A4 (de) 2010-04-05 2014-01-15 Univ Chicago Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
EP2593133A4 (de) 2010-07-13 2014-11-26 Merck Sharp & Dohme Staphylococcus aureus-oberflächenprotein sa1789 und darauf basierender schutzimpfstoff
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
WO2012065034A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2013034736A1 (en) * 2011-09-08 2013-03-14 Umc Utrecht Holding B.V. Use of staphylococcal superantigen- like 3 (ssl3) as an tlr2 inhibitor
WO2013066731A2 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2451 protein
WO2013162746A1 (en) 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
EP2872173A4 (de) 2012-07-10 2016-03-23 Merck Sharp & Dohme Schutzimpfstoff auf grundlage des staphylococcus-aureus-proteins sa2493
CA2879272A1 (en) 2012-07-16 2014-01-23 Robert G.K. DONALD Saccharides and uses thereof
CA3139981A1 (en) 2019-05-14 2020-11-19 The University Of Chicago Methods and compositions comprising staphylococcus protein a (spa) variants
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4425330A (en) * 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
CA2097912A1 (en) * 1991-10-09 1993-04-10 Yoshiyuki Kamio Method of detecting methicillin-resistant staphylococcus aureus, novel peptides, and dnas encoding the same
US6008341A (en) * 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
WO1997014801A1 (en) * 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel cell surface protein compounds
US6737248B2 (en) * 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6288214B1 (en) * 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
US6617156B1 (en) * 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
GB9806762D0 (en) * 1998-03-31 1998-05-27 Neutec Pharma Plc Treatment and diagnosis of staphylococcal infections
EP2330192A1 (de) * 1998-08-31 2011-06-08 The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Polypeptide und Polynukleotide aus coagulase-negativen Staphylokokken
IL141639A (en) * 1998-08-31 2005-12-18 Inhibitex Inc Multicomponent vaccines
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus

Also Published As

Publication number Publication date
NO20025838D0 (no) 2002-12-05
BR0111823A (pt) 2003-06-10
US20060140979A1 (en) 2006-06-29
CA2805216A1 (en) 2001-12-27
EP1710311A3 (de) 2007-09-19
EP1710311B1 (de) 2011-09-14
AU2007200937B2 (en) 2009-11-12
CA2412504A1 (en) 2001-12-27
HK1051873A1 (en) 2003-08-22
EP2269634A3 (de) 2011-04-06
DE60132893D1 (de) 2008-04-03
EP1292681A1 (de) 2003-03-19
WO2001098499A1 (en) 2001-12-27
AU2001274248B2 (en) 2007-09-13
AU2007200937A8 (en) 2010-01-28
DE60132893T2 (de) 2009-03-12
EP2287316A1 (de) 2011-02-23
AU2007200937B8 (en) 2010-01-28
CA2412504C (en) 2013-04-16
GB0014907D0 (en) 2000-08-09
ATE386806T1 (de) 2008-03-15
CN102021184A (zh) 2011-04-20
EP2269634A2 (de) 2011-01-05
US7585658B2 (en) 2009-09-08
JP2012044991A (ja) 2012-03-08
AU2007200937A1 (en) 2007-03-22
CN1437653A (zh) 2003-08-20
AU2010200510A1 (en) 2010-03-04
US8568731B2 (en) 2013-10-29
EP1710311A2 (de) 2006-10-11
JP2004500883A (ja) 2004-01-15
US20030186275A1 (en) 2003-10-02
AU7424801A (en) 2002-01-02
EP1292681B1 (de) 2008-02-20
US20100166792A1 (en) 2010-07-01
NO20025838L (no) 2003-02-18

Similar Documents

Publication Publication Date Title
ATE386806T1 (de) Antigene polypeptide
ATE542829T1 (de) Impfstoff
AP2001002199A0 (en) Novel streptococcus antigens
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
ATE475675T1 (de) Verwendung prokariotischer pest-ähnlicher peptide zur verstärkung der immunogenität von antigenen
BR0206565A (pt) Arranjo de antìgeno molecular
NO20033364D0 (no) Fremgangsmåte for identifikasjon, isolasjon og produksjon av antigener tilet spesifikt patogen
EE200700052A (et) Antikeha he v?i mitme apo-lipoproteiin B fragmendi vastu
DE60117164D1 (de) Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
DK1328547T3 (da) Identifikation og modifikation af immundominante epitoper i polypeptider
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
ATE286745T1 (de) Verwendung von antikörpern zur vakzinierung gegen krebs
DE60132427D1 (de) Gebrauch von opri lipoprotein aus pseudomonas als th1 induzierendes natürliches adjuvans für heterologe antigene
DK1370284T3 (da) Bakteriofag-medieret immunisering
WO2001004143A3 (en) Prostase vaccine
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
EP1090995A3 (de) Mycoplasma hyopneumoniae Antigen MHP3, dafür kodierendes Gen und Ihre Verwendungen
GB0409559D0 (en) Polypeptide
DK1245677T3 (da) Nukleinsyrer og proteiner af Mycoplasma hyopneumoniae mhp3-genet og anvendelser deraf
EP1401470A4 (de) Neue antikörper, die an antigene polypeptide binden, die antigene kodierende nukleinsäuren und verfahren zu ihrer anwendung
FR2839721B1 (fr) Antigene polypeptidique induisant des anticorps neutralisant le vih

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties